The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Triple‐Negative Breast Cancer Chemoimmunotherapy
In article number 2302834, Kaipei Luo, Xiaofang Li, and co‐workers develop a LyP‐1 and chondroitin sulfate dual‐modified liposome co‐loading paclitaxel and cryptotanshinone. The liposome enhances cellular uptake via p32/CD44 dual receptor‐mediated endocytosis, and achieves potent triple‐negative breast cancer chemoimmunotherapy through inducing immunogenic...
Immunotherapy gains increasing focus in treating triple‐negative breast cancer (TNBC), while its efficacy is greatly restricted owing to low tumor immunogenicity and immunosuppressive tumor microenvironment (ITM). Herein, a LyP‐1 and chondroitin sulfate (CS) dual‐modified liposome co‐loaded with paclitaxel (PTX) and cryptotanshinone (CTS), namely CS/LyP‐1‐PC Lip, is engineered for TNBC chemoimmunotherapy...